|
|
Volumn 109, Issue 5, 2012, Pages 645-646
|
|
Should we really consider Gleason 6 prostate cancer?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
PROSTATE CANCER ANTIGEN 3;
PROSTATE SPECIFIC ANTIGEN;
TUMOR ANTIGEN;
UNCLASSIFIED DRUG;
ANXIETY;
CANCER DIAGNOSIS;
CANCER GENETICS;
CANCER GRADING;
CANCER GROWTH;
CANCER INVASION;
CANCER MORTALITY;
CANCER RISK;
CANCER THERAPY;
CLINICAL ASSESSMENT;
DISEASE ASSOCIATION;
DISEASE COURSE;
DISEASE SURVEILLANCE;
EARLY DIAGNOSIS;
GLEASON SCORE;
HUMAN;
IMMUNOHISTOCHEMISTRY;
METASTASIS;
MOLECULAR GENETICS;
NOTE;
PATHOLOGIST;
PATIENT ASSESSMENT;
PATIENT ATTITUDE;
PATIENT CODING;
PRIORITY JOURNAL;
PROSTATE CANCER;
PROSTATECTOMY;
PROSTATIC INTRAEPITHELIAL NEOPLASIA;
PROTEIN BLOOD LEVEL;
TUMOR BIOPSY;
UROLOGIST;
HUMANS;
MALE;
NEOPLASM GRADING;
PROSTATIC NEOPLASMS;
|
|
EID: 84857359652
PISSN: 14644096
EISSN: 1464410X
Source Type: Journal
DOI: 10.1111/j.1464-410X.2011.10854.x Document Type: Note |
|
Times cited : (27)
|
|
References (0)
|
